Condition or Therapy:

Leukemia and lymphoma 


Cancer and Blood Disorders

What is the goal of this study?

PLAT-04 is a phase 1 trial that tests the safety and feasibility of CAR T cells that have been reprogrammed to target the CD22 protein expressed by some leukemia cells.

The PLAT-02 trial uses CAR T cells that have been reprogrammed to target the CD19 protein. However, in some patients, the leukemia comes back (recurs) and has evolved so it doesn’t express CD19 anymore, but it continues to express another protein, CD22.

Our researchers developed PLAT-04 as an investigational treatment option that will hopefully lead to long-term remission for patients whose cancer expresses CD22.

Learn how CAR T-cell therapy works

Who can join the study?

This study might be a good fit for children and young adults who:

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about the PLAT-04 study at

Who can I contact for more information?

Please email or call us at 206-987-2106 to learn more about the study.

Learn about other PLAT studies at Seattle Children's:

  • PLAT-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T-Cell Immunotherapy for CD19+ Leukemia
  • PLAT-03: A Pilot Feasibility and Safety Study of CD19t T-APC Vaccination Following CAR T-Cell Immunotherapy for CD19+ Leukemia
  • PLAT-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T-Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
  • PLAT-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

Study Location(s):

Seattle Children's Hospital main campus 

Principal Investigator:

Dr. Corrine Summers